Returning individual clinical trial data to patients has become a pressing ethical and practical issue. As trials grow more complex and participant investment increases, the drive to honor their contributions and expectations through returning data aligns with key ethical principles rooted in
In a significant move aimed at enhancing New Zealand’s public health landscape, Health Minister Dr. Shane Reti has announced new guidelines for the Health Research Council (HRC) of New Zealand. These guidelines emphasize a targeted approach, ensuring that research funding aligns closely with g
Johnson & Johnson (J&J) recently announced a significant shift in their approach to the 340B drug discount program, aiming to change how discounts are offered for crucial medications. This policy adjustment is set to take effect on October 15, 2024, and has raised considerable concerns
In recent years, the focus on perioperative care for older patients has become a critical concern, particularly for those undergoing elective hip and knee replacements. This concern is emphasized in Australia, where a significant population of elderly individuals requires such surgeries. A
The current status of mpox in Wales, as confirmed by Public Health Wales, provides a cautious yet reassuring outlook for the region. With no cases of Clade I mpox or any other variant reported within Wales, Public Health Wales maintains that the overall risk to the UK population remains low.
CluePoints, a standout innovator in the pharmaceutical and healthcare sectors, is spearheading significant changes through advancements in Risk-Based Quality Management (RBQM) and centralized monitoring. This article delves into various facets of these developments, drawing insights from Francois
